| Pharmaceutical Information |
| Drug Name |
Omadacycline |
| Drug ID |
BADD_D02575 |
| Description |
Omadacycline has been used in trials studying the treatment of Bacterial Pneumonia, Bacterial Infections, Community-Acquired Infections, and Skin Structures and Soft Tissue Infections. Omadacycline represents a significant advance over the well-known tetracycline family, and has been shown to be highly effective in animal models at treating increasingly problematic, clinically prevalent infections caused by gram-positive bacteria, such as methicillin-resistant Staphylococcus aureus (MRSA), and by gram-negative, atypical and anaerobic bacteria, including those resistant to currently available classes of antibiotics and known to cause diseases such as pneumonias, urinary tract infections, skin diseases and blood-borne infections in both the hospital and community settings. |
| Indications and Usage |
Omadacycline is indicated for the treatment of community acquired bacterial pneumonia and acute bacterial skin and skin structure infections caused by omadacycline-susceptible organisms in adults.[FDA Label] |
| Marketing Status |
approved; investigational |
| ATC Code |
J01AA15 |
| DrugBank ID |
DB12455
|
| KEGG ID |
D09647
|
| MeSH ID |
C000591640
|
| PubChem ID |
Not Available
|
| TTD Drug ID |
D09GUJ
|
| NDC Product Code |
68225-111; 71715-001; 71715-002 |
| UNII |
090IP5RV8F
|
| Synonyms |
omadacycline | nuzyra |
|
| Chemical Information |
| Molecular Formula |
Not Available |
| CAS Registry Number |
389139-89-3 |
| SMILES |
Not Available |
| Chemical Structure |
|
|
| ADRs Induced by Drug |
|
|
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
|
|
|
